Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
An overview of the entities responsible for stock index governance, outlining roles, responsibilities, and the importance of transparent oversight.
16,186 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Netflix has stumbled this year, leaving many investors wondering what comes next. This guide explains the drop, what ...
Tesla faces a pivotal three-year outlook as margins recover and AI initiatives expand. Analysts sketch a base case ar...
Five of america's biggest banks kick off a pivotal earnings week. Here's what to watch as each reports and how the re...
Two giants in chip-design software compete for your next tech stock buy. This guide breaks down Cadence Design System...
Netflix just changed how it reports engagement, and the move could ripple through NFLX stock moves. This guide breaks...
Capital Group's Dividend Value ETF has significantly outperformed SCHD since February 2022, prompting renewed debate ...
Blue (OBDC) 2025 earnings could signal how well the firm leverages private credit trends and cost discipline. This gu...
As biotech manufacturing accelerates, repligen (rgen) 2025 earnings will shape how investors price the stock. This gu...
A practical, investor-focused look at delcath (dcth) 2025 earnings prospects. We break down the catalysts, risks, and...
Credo Technology is set to report after the close, with investors watching margins and guidance as the stock prices i...
Marvell Technology is poised to release earnings later this week, with investors focused on AI chip orders and optica...